AVACEN Medical launches $2M advertising campaign in response to positive outcomes of fibromyalgia study AVACEN Medical announced today that it has launched a $2 million campaign on Crowdfunder.com to support further firm clinical FDA and trials applications. That is in response to the encouraging outcomes of an AVACEN sponsored pilot and a follow-up fibromyalgia research involving 22 subjects and separate anecdotal results relating to other common medical conditions What are the side effects of acyclovir 800 mg? . These results were derived from an AVACEN therapeutic medical device and treatment method that noninvasively transfers high temperature into the circulatory system. Fibromyalgia affects around 200 to 400 million people worldwide according to The National Fibromyalgia Association.
Another secondary endpoint was time until occurrence of a composite of cardiovascular events comprising cerebral events, coronary events, cardiac occasions, aortic/peripheral arterial events, complication of diabetes, and aggravation of renal function.2 mg/g Cr in the ARB group compared to a loss of 4.1 mg/g Cr in the non-ARB group . Similarly, plasma BNP had elevated by 0.5 pg/ml in the ARB group and by 3.8 pg/ml in the non-ARB group . Fewer cardiovascular events occurred in the ARB group, but the difference had not been statistically significant . Other biomarkers weren’t different between your two groups except for serum adiponectin, which showed a larger increase , indicating better CVD wellness, and eGFR which showed a larger decrease indicating poorer renal function in the ARB group compared to the non-ARB group.